BA
KERX

Bristol Advisors’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Bristol Advisors’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-51,100
Closed -$174K – 86
2018
Q3 		$174K Buy
51,100
+50,000
+4,545% +$180K 0.29% 42
2018
Q2 		$4K Hold
1,100
– – 0.01% 63
2018
Q1 		$4K Sell
1,100
-190,000
-99% -$885K 0.01% 28
2017
Q4 		$889K Buy
191,100
+168,650
+751% +$929K 0.56% 35
2017
Q3 		$251K Buy
+22,450
New +$161K 0.25% 56

Bristol Advisors's KERX Position: Q4 2018 in Review

Bristol Advisors sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 51,100 shares — an estimated $174K sold.

Bristol Advisors first reported a position in KERX in Q3 2017 and held it in 5 quarters. The position peaked at $889K in Q4 2017. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.

  • Bristol Advisors reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
  • Bristol Advisors sold 51,100 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $174K.
  • Bristol Advisors first reported a position in Keryx Biopharmaceuticals Inc in Q3 2017 and held it in 5 quarters.
  • Bristol Advisors's Keryx Biopharmaceuticals Inc position peaked at $889K in Q4 2017.
  • 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.

Based on Bristol Advisors's 13F filing for Q4 2018, filed 14 Jan 2019.